Parabilis Medicines
Updated: January 08, 2026
CEO - Mathai Mammen
Country: USA | Funding: $305M (+)
Founded: 2016
Website: https://parabilismed.com
Parabilis Medicines has developed drug discovery platform for alpha-helical-linked peptides, primarily composed of specially selected non-canonical amino acids. Using this platform, Parabilis has assembled a large set of non-canonical amino acids and has hundreds of proprietary linkers for stabilizing peptides in the alpha-helical conformation. To fully exploit this diversity, the company has developed a suite of specialized experimental systems that can generate massive amounts of data on a wide range of drug properties, providing both input for building artificial intelligence models and serving as a high-throughput platform for empirically validating model predictions. As a pilot project, the company is advancing a drug against desmoid tumors.
Founded: 2016
Website: https://parabilismed.com
Parabilis Medicines has developed drug discovery platform for alpha-helical-linked peptides, primarily composed of specially selected non-canonical amino acids. Using this platform, Parabilis has assembled a large set of non-canonical amino acids and has hundreds of proprietary linkers for stabilizing peptides in the alpha-helical conformation. To fully exploit this diversity, the company has developed a suite of specialized experimental systems that can generate massive amounts of data on a wide range of drug properties, providing both input for building artificial intelligence models and serving as a high-throughput platform for empirically validating model predictions. As a pilot project, the company is advancing a drug against desmoid tumors.
